Detection of Neutralizing Antibodies in COVID-19 Patients from Steve Biko Academic Hospital Complex: A Pilot Study
A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus disease 2019 (COVID-19) has been demonstrated by several studies. Here, we detect SARS-CoV-2 neutralizing antibody (NAB) production in COVID...
Saved in:
Published in | COVID Vol. 3; no. 7; pp. 999 - 1010 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
MDPI AG
01.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus disease 2019 (COVID-19) has been demonstrated by several studies. Here, we detect SARS-CoV-2 neutralizing antibody (NAB) production in COVID-19 patients from the Steve Biko Academic Hospital complex (SBAH), South Africa (SA). Samples from COVID-19 patients (mild to severe) were collected. SARS-CoV-2 rapid assays, genotyping (Delta and Omicron variants) and enzyme-linked immunosorbent assays (ELISA) were performed. IBM® Statistical Package for the Social Sciences (SPSS®) version 28 was used for inferential statistical analysis, and the data were presented using the Prism9 software (version 9.4.1). A total of 137 laboratory-confirmed COVID-19 patients, 12 vaccine recipients and 8 unvaccinated participants were evaluated. The production of SARS-CoV-2 NABs was observed in some of the COVID-19 cases, mainly in severe cases, although this should be noted with caution due to the small sample size of this pilot study. NABs were also observed in asymptomatic participants, with the most being found in recipients (n = 6) of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. We found a strong presence of NABs in COVID-19 patients, specifically in mild and severe cases. Severe infection was associated with higher NAB production (82%). |
---|---|
AbstractList | A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus disease 2019 (COVID-19) has been demonstrated by several studies. Here, we detect SARS-CoV-2 neutralizing antibody (NAB) production in COVID-19 patients from the Steve Biko Academic Hospital complex (SBAH), South Africa (SA). Samples from COVID-19 patients (mild to severe) were collected. SARS-CoV-2 rapid assays, genotyping (Delta and Omicron variants) and enzyme-linked immunosorbent assays (ELISA) were performed. IBM® Statistical Package for the Social Sciences (SPSS®) version 28 was used for inferential statistical analysis, and the data were presented using the Prism9 software (version 9.4.1). A total of 137 laboratory-confirmed COVID-19 patients, 12 vaccine recipients and 8 unvaccinated participants were evaluated. The production of SARS-CoV-2 NABs was observed in some of the COVID-19 cases, mainly in severe cases, although this should be noted with caution due to the small sample size of this pilot study. NABs were also observed in asymptomatic participants, with the most being found in recipients (n = 6) of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. We found a strong presence of NABs in COVID-19 patients, specifically in mild and severe cases. Severe infection was associated with higher NAB production (82%). |
Author | Mzizi, Yonwaba Mayaphi, Simnikiwe Sathekge, Mike Xu, Shuting Damane, Botle Precious Chalwe, Joseph Musonda Vorster, Mariza Hairwadzi, Henry Rodrigues, Hosana Gomes van der Westhuizen, Donald Ndlovu, Honest Kgatle, Mankgopo Zongo, Lusanda Ueckermann, Veronica Mathebela, Precious Zeevaart, Jan Rijn Moura-Alves, Pedro |
Author_xml | – sequence: 1 givenname: Mankgopo surname: Kgatle fullname: Kgatle, Mankgopo – sequence: 2 givenname: Joseph Musonda orcidid: 0000-0001-9148-9224 surname: Chalwe fullname: Chalwe, Joseph Musonda – sequence: 3 givenname: Donald surname: van der Westhuizen fullname: van der Westhuizen, Donald – sequence: 4 givenname: Shuting surname: Xu fullname: Xu, Shuting – sequence: 5 givenname: Botle Precious orcidid: 0000-0003-3060-5572 surname: Damane fullname: Damane, Botle Precious – sequence: 6 givenname: Precious orcidid: 0000-0003-2794-0222 surname: Mathebela fullname: Mathebela, Precious – sequence: 7 givenname: Veronica orcidid: 0000-0002-4419-3583 surname: Ueckermann fullname: Ueckermann, Veronica – sequence: 8 givenname: Simnikiwe orcidid: 0000-0002-5453-4353 surname: Mayaphi fullname: Mayaphi, Simnikiwe – sequence: 9 givenname: Hosana Gomes orcidid: 0000-0002-6122-0379 surname: Rodrigues fullname: Rodrigues, Hosana Gomes – sequence: 10 givenname: Pedro orcidid: 0000-0003-4337-9113 surname: Moura-Alves fullname: Moura-Alves, Pedro – sequence: 11 givenname: Honest surname: Ndlovu fullname: Ndlovu, Honest – sequence: 12 givenname: Yonwaba surname: Mzizi fullname: Mzizi, Yonwaba – sequence: 13 givenname: Lusanda orcidid: 0000-0001-7840-7386 surname: Zongo fullname: Zongo, Lusanda – sequence: 14 givenname: Henry surname: Hairwadzi fullname: Hairwadzi, Henry – sequence: 15 givenname: Mariza surname: Vorster fullname: Vorster, Mariza – sequence: 16 givenname: Jan Rijn orcidid: 0000-0003-0794-3012 surname: Zeevaart fullname: Zeevaart, Jan Rijn – sequence: 17 givenname: Mike orcidid: 0000-0002-2806-0625 surname: Sathekge fullname: Sathekge, Mike |
BookMark | eNpNkFtLAzEUhIMoeH3zB-QHuJo9Zze78a3WSwtiBS-vS5qclOh2U7JpUX-91Yr0aYZh-GDmkO12oSPGTnNxjqjEhQkrb1FUQlSwww5AVpjVeQ67W36fnfT9mxAC6gpBwQGL15TIJB86Hhx_oGWKuvVfvpvxQZf8NFhPPfcdH05ex9dZrvijTp661HMXw5w_JVoRv_LvgQ-MtjT3ho9Cv_BJt3wY5ouWPi75gD_6NqR1e2k_j9me021PJ396xF5ub56Ho-x-cjceDu4zg4Apk7pUVEkyAK6wSgAYLGqopCxlYSWqwhlNVk0Loyzq9RqweSnFOnc1FAqP2HjDtUG_NYvo5zp-NkH75jcIcdbomLxpqbECJSGAds4WaO20qnCqoSzLXNeqxjXrbMMyMfR9JPfPy0Xzc3-zfT9-A7DpeTg |
Cites_doi | 10.1038/s41591-020-0869-5 10.1016/j.ebiom.2021.103622 10.1001/jama.2022.1393 10.3389/fimmu.2021.633184 10.3390/vaccines9121376 10.1038/s41591-022-01816-0 10.3390/vaccines11020224 10.1016/S0140-6736(21)02835-X 10.1001/jama.2020.1585 10.1186/s12985-023-01974-8 10.1038/s41591-021-01377-8 10.3389/fimmu.2022.928501 10.1093/ofid/ofac135 10.1126/science.abm8108 10.1016/j.jaci.2009.09.017 10.1002/bies.201200099 10.1056/NEJMoa2119658 10.1101/2021.07.19.452771 10.3389/fmicb.2021.803031 10.1371/journal.pone.0258421 10.3389/fimmu.2021.681449 10.7326/M20-5926 10.1126/science.abe1107 10.1080/25765299.2021.1903144 10.2147/IDR.S373183 10.1016/j.cca.2021.10.028 10.1007/s11302-021-09814-6 10.1002/iid3.580 10.1016/j.medj.2021.01.005 10.1016/j.ajpath.2020.08.009 10.1016/j.jcv.2022.105253 10.1038/s41586-021-03207-w 10.1038/s41591-020-1051-9 10.1056/NEJMra2206573 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.3390/covid3070072 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2673-8112 |
EndPage | 1010 |
ExternalDocumentID | oai_doaj_org_article_d036e322affd43ddb773ba25551a8983 10_3390_covid3070072 |
GroupedDBID | AAYXX ABDBF AFZYC ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ MODMG M~E OK1 |
ID | FETCH-LOGICAL-c323t-6a59e76ec22f4d9022c3482766564d6394fcaed9b4c9d3a2922d156094ff82493 |
IEDL.DBID | DOA |
ISSN | 2673-8112 |
IngestDate | Wed Aug 27 01:28:03 EDT 2025 Tue Jul 01 02:20:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c323t-6a59e76ec22f4d9022c3482766564d6394fcaed9b4c9d3a2922d156094ff82493 |
ORCID | 0000-0003-3060-5572 0000-0003-0794-3012 0000-0002-4419-3583 0000-0001-9148-9224 0000-0002-6122-0379 0000-0003-4337-9113 0000-0003-2794-0222 0000-0001-7840-7386 0000-0002-5453-4353 0000-0002-2806-0625 |
OpenAccessLink | https://doaj.org/article/d036e322affd43ddb773ba25551a8983 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d036e322affd43ddb773ba25551a8983 crossref_primary_10_3390_covid3070072 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-07-01 |
PublicationDateYYYYMMDD | 2023-07-01 |
PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | COVID |
PublicationYear | 2023 |
Publisher | MDPI AG |
Publisher_xml | – name: MDPI AG |
References | Velilla (ref_11) 2021; 12 Yan (ref_14) 2022; 12 Alejo (ref_18) 2022; 327 Zahid (ref_24) 2021; 28 Nam (ref_15) 2021; 9 Nehme (ref_2) 2021; 174 Ng (ref_25) 2020; 370 ref_35 ref_34 Acharya (ref_37) 2022; 9 Wang (ref_4) 2020; 323 Merad (ref_12) 2022; 375 Bonnet (ref_31) 2021; 73 Khoury (ref_13) 2021; 27 ref_39 Reynolds (ref_26) 2022; 15 Oh (ref_19) 2022; 155 Osterhaus (ref_9) 2021; 12 Pradenas (ref_22) 2021; 2 Pang (ref_6) 2021; 8 Barouch (ref_21) 2022; 387 Puhach (ref_38) 2022; 28 Lam (ref_17) 2020; 184 Klein (ref_10) 2012; 34 Dadras (ref_33) 2021; 10 ref_23 Bonilla (ref_8) 2010; 125 ref_1 He (ref_3) 2020; 26 Sejdic (ref_7) 2023; 20 Gaebler (ref_20) 2021; 591 Madhi (ref_28) 2022; 386 Arankalle (ref_36) 2022; 13 Padoan (ref_16) 2021; 523 ref_5 Huang (ref_32) 2020; 26 Gustine (ref_30) 2020; 191 Hasan (ref_29) 2021; 18 McIntyre (ref_27) 2021; 399 |
References_xml | – volume: 26 start-page: 672 year: 2020 ident: ref_3 article-title: Temporal dynamics in viral shedding and transmissibility of COVID-19 publication-title: Nat. Med. doi: 10.1038/s41591-020-0869-5 – volume: 73 start-page: 103622 year: 2021 ident: ref_31 article-title: Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation publication-title: Ebiomedicine doi: 10.1016/j.ebiom.2021.103622 – volume: 327 start-page: 1085 year: 2022 ident: ref_18 article-title: Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19 publication-title: JAMA doi: 10.1001/jama.2022.1393 – ident: ref_5 – volume: 12 start-page: 633184 year: 2021 ident: ref_11 article-title: Antibody Responses in COVID-19: A Review publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.633184 – ident: ref_35 doi: 10.3390/vaccines9121376 – volume: 28 start-page: 1491 year: 2022 ident: ref_38 article-title: Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 publication-title: Nat. Med. doi: 10.1038/s41591-022-01816-0 – volume: 8 start-page: 47 year: 2021 ident: ref_6 article-title: Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice publication-title: Mil. Med. Res. – ident: ref_39 doi: 10.3390/vaccines11020224 – volume: 399 start-page: 406 year: 2021 ident: ref_27 article-title: COVID-19 vaccine strategies must focus on severe disease and global equity publication-title: Lancet doi: 10.1016/S0140-6736(21)02835-X – volume: 323 start-page: 1061 year: 2020 ident: ref_4 article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China publication-title: JAMA doi: 10.1001/jama.2020.1585 – volume: 20 start-page: 14 year: 2023 ident: ref_7 article-title: High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients publication-title: Virol. J. doi: 10.1186/s12985-023-01974-8 – volume: 27 start-page: 1205 year: 2021 ident: ref_13 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat. Med. doi: 10.1038/s41591-021-01377-8 – volume: 13 start-page: 1 year: 2022 ident: ref_36 article-title: Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.928501 – volume: 9 start-page: ofac135 year: 2022 ident: ref_37 article-title: Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant publication-title: Open Forum Infect. Dis. doi: 10.1093/ofid/ofac135 – volume: 375 start-page: 1122 year: 2022 ident: ref_12 article-title: The immunology and immunopathology of COVID-19 publication-title: Science doi: 10.1126/science.abm8108 – ident: ref_1 – volume: 125 start-page: S33 year: 2010 ident: ref_8 article-title: Adaptive immunity publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2009.09.017 – volume: 34 start-page: 1050 year: 2012 ident: ref_10 article-title: Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases publication-title: Bioessays doi: 10.1002/bies.201200099 – volume: 386 start-page: 1314 year: 2022 ident: ref_28 article-title: Population Immunity and COVID-19 Severity with Omicron Variant in South Africa publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2119658 – ident: ref_23 doi: 10.1101/2021.07.19.452771 – volume: 12 start-page: 803031 year: 2022 ident: ref_14 article-title: Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection publication-title: Front. Microbiol. doi: 10.3389/fmicb.2021.803031 – ident: ref_34 doi: 10.1371/journal.pone.0258421 – volume: 12 start-page: 681449 year: 2021 ident: ref_9 article-title: Aging and Options to Halt Declining Immunity to Virus Infections publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.681449 – volume: 174 start-page: 723 year: 2021 ident: ref_2 article-title: COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings publication-title: Ann. Intern. Med. doi: 10.7326/M20-5926 – volume: 370 start-page: 1339 year: 2020 ident: ref_25 article-title: Preexisting and de novo humoral immunity to SARS-CoV-2 in humans publication-title: Science doi: 10.1126/science.abe1107 – volume: 28 start-page: 225 year: 2021 ident: ref_24 article-title: A review on COVID-19 vaccines: Stages of clinical trials, mode of actions and efficacy publication-title: Arab J. Basic Appl. Sci. doi: 10.1080/25765299.2021.1903144 – volume: 15 start-page: 5167 year: 2022 ident: ref_26 article-title: COVID-19 vaccination breakthrough infections in a real-world setting: Using community reporters to evaluate vaccine effectiveness publication-title: Infect. Drug Resist. doi: 10.2147/IDR.S373183 – volume: 523 start-page: 446 year: 2021 ident: ref_16 article-title: SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2021.10.028 – volume: 18 start-page: 13 year: 2021 ident: ref_29 article-title: A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling publication-title: Purinergic Signal. doi: 10.1007/s11302-021-09814-6 – volume: 10 start-page: e580 year: 2021 ident: ref_33 article-title: The relationship between COVID-19 viral load and disease severity: A systematic review publication-title: Immun. Inflamm. Dis. doi: 10.1002/iid3.580 – volume: 2 start-page: 313 year: 2021 ident: ref_22 article-title: Stable neutralizing an-tibody levels 6 months after mild and severe COVID-19 episodes publication-title: Med doi: 10.1016/j.medj.2021.01.005 – volume: 191 start-page: 4 year: 2020 ident: ref_30 article-title: Immunopathology of Hyperinflammation in COVID-19 publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2020.08.009 – volume: 9 start-page: 3 year: 2021 ident: ref_15 article-title: Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay publication-title: ASM J. – volume: 184 start-page: 476 year: 2020 ident: ref_17 article-title: COVID-19-neutralizing antibodies predict disease severity and survival publication-title: Cell – volume: 155 start-page: 105253 year: 2022 ident: ref_19 article-title: Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2022.105253 – volume: 591 start-page: 639 year: 2021 ident: ref_20 article-title: Evolution of antibody immunity to SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-021-03207-w – volume: 26 start-page: 1636 year: 2020 ident: ref_32 article-title: An inflammatory cytokine signature predicts COVID-19 severity and survival publication-title: Nat. Med. doi: 10.1038/s41591-020-1051-9 – volume: 387 start-page: 1011 year: 2022 ident: ref_21 article-title: COVID-19 vaccines—Immunity, variants, boosters publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra2206573 |
SSID | ssj0002873292 |
Score | 2.2244987 |
Snippet | A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus... |
SourceID | doaj crossref |
SourceType | Open Website Index Database |
StartPage | 999 |
SubjectTerms | COVID-19 ELISA neutralizing antibodies SARS-CoV-2 South Africa Steve Biko Academic Hospital |
Title | Detection of Neutralizing Antibodies in COVID-19 Patients from Steve Biko Academic Hospital Complex: A Pilot Study |
URI | https://doaj.org/article/d036e322affd43ddb773ba25551a8983 |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF6kJy-iqFhfzEGPoWl2k0289YkKrT1Y6S3sE6olkZqCevC3O7tppZ68eMlhCCHMTDLfLN98Q8gV2mMhuAnSxCYBU0oFgocyoCaUbYU4SXrFm9E4uZ2y-1k821r15ThhtTxw7biWxl-swawT1mpGtZacUykQCMdtkWap1_nEmrfVTD37IyNOoyyqme4U-_qWcnNtLsFDHv2qQVtS_b6mDPfJ3hoMQqd-iQOyY4pDsuybyvOjCigtjM3Kn0V8YomBTlHNZel4fzAvoPfwdNcP2hlMam3UN3CzIuD3lEF3_lLChvwOm-0g4D7_hXm_gQ5M5ouyAscj_Dgi0-HgsXcbrDcjBIpGtAoSEWeGJ0ZFkWU6wzqsnEgNTxCdMY2gg1kljM4kU5mmAj0RaTcyjXabYsNFj0mjKAtzQiBBPMEMp0yxlFmhZJwqbZVE6GJjxcImud74Kn-tBTBybBycT_NtnzZJ1zny5x4nW-0NGMx8Hcz8r2Ce_sdDzsiu2wlfc2rPSaNarswFIodKXvokwevoa_ANZ4TDcg |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection+of+Neutralizing+Antibodies+in+COVID-19+Patients+from+Steve+Biko+Academic+Hospital+Complex%3A+A+Pilot+Study&rft.jtitle=COVID&rft.au=Mankgopo+Kgatle&rft.au=Joseph+Musonda+Chalwe&rft.au=Donald+van+der+Westhuizen&rft.au=Shuting+Xu&rft.date=2023-07-01&rft.pub=MDPI+AG&rft.eissn=2673-8112&rft.volume=3&rft.issue=7&rft.spage=999&rft.epage=1010&rft_id=info:doi/10.3390%2Fcovid3070072&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d036e322affd43ddb773ba25551a8983 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2673-8112&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2673-8112&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2673-8112&client=summon |